More News

National framework to strengthen UK advanced therapy clinical trials

Jim Cornall -
A new framework designed to support the standardisation and expansion of advanced therapy clinical trials has launched in the...

Sensor detects Alzheimer’s and Parkinson’s in blood

Jim Cornall -
For the first time, therapeutically effective medications are now available for Alzheimer’s disease. Effective symptomatic therapies also exist for...

Base to Base biotech podcast 60: Delivery method reduces prostate cancer tumour size

Jim Cornall -
This week, we have a conversation with the founder, director and chief scientific advisor of Alessa Therapeutics, Pamela Munster. Base...

Pilot trial suggests anti-inflammatory drug could help difficult-to-treat depression

Jim Cornall -
Immunotherapy could be a promising new treatment option for patients with difficult-to-treat depression. This is a key finding from...

Global collaboration on Kawasaki disease key to reducing risk of serious heart conditions

Jim Cornall -
International collaboration in research, diagnosis and care is critical to reducing the risk of serious heart conditions for children...

Phase 1b data from post-immunotherapy hepatocellular carcinoma in liver cancer shared

Jim Cornall -
Agenus Inc. has announced the publication of phase 1b data evaluating botensilimab (BOT), an Fc-enhanced anti-CTLA-4 antibody, in combination...

Promising results from LGMD-R5 limb-girdle muscular dystrophy gene therapy trial

Jim Cornall -
Atamyo Therapeutics, which specialises in the development of gene therapies for limb-girdle muscular dystrophy (LGMD), has announced the first...

ADDF praises Alzheimer’s drug progress

Jim Cornall -
Biogen has announced topline results from its phase 2 CELIA study of diranersen, an investigational therapy designed to target...

Challenging assumptions about lymph node radiation therapy in breast cancer

Jim Cornall -
Final results from an EORTC randomised trial with more than 20 years of follow-up show that irradiation of the...

Proteins that drive fibrosis can be blocked

Jim Cornall -
The liver is often called a “silent organ,” as it can sustain significant damage without obvious symptoms. But when...

New drug candidate shows promise as brain cancer treatment

Jim Cornall -
A next-generation cancer therapy being developed at McMaster University in Canada has shown early promise as a treatment candidate...

Blood test that detects tumour DNA could help guide treatment when cancer has spread

Jim Cornall -
A blood test that detects tumour DNA circulating in the bloodstream may help select the most effective treatment options...

Hereditary epilepsy treatment

Jim Cornall -
In a world first, a research team at the University of Zurich has successfully treated mice carrying an inherited...

Myelin, a new brain regulator

Jim Cornall -
A study by Carlos Matute of the EHU-University of the Basque Country reinforces a paradigm shift in neuroscience: myelin...

Lab-designed molecule offers promising alternative for coeliac disease

Jim Cornall -
A research project led by the Institute for Research in Nutrition and Food Safety (INSA) and the Faculty of...

Base to Base biotech podcast 59: DIA helping biotech thrive, and Gorlin syndrome

Jim Cornall -
This week, we have conversations with DIA chief science and regulatory officer, Maria Vassileva, and Medicus Pharma CEO, Raza...

Positive data from AMD treatment trial

Jim Cornall -
MingMed Biotechnology Co., Ltd has announced positive results from its phase II clinical trial of QA102 in patients with...

‘Hidden switch’ in immune cells helps kill deadly fungus

Jim Cornall -
Scientists at the University of East Anglia in the UK have contributed to discovering a “control switch” inside immune...

Asthma drug in China moves forward

Jim Cornall -
Chance Pharmaceuticals has announced that the Center for Drug Evaluation of China's National Medical Products Administration (NMPA) has accepted...

New coalition forms to boost US biotech

Jim Cornall -
The American Biotech Innovation Alliance (ABIA) has announced its launch, bringing together biotechnology leaders from across the US around...

Advancing Aramchol-based therapeutics

Jim Cornall -
Tissue Dynamics Ltd. and Galmed Pharmaceuticals Ltd. have announced a collaboration to develop a novel human chronic cardiac fibrosis...